Breaking Stories

The Wall Street Journal: FDA, J&J set to announce Baltimore vaccine plant ready to reopen


WASHINGTON — The Food and Drug Administration and vaccine maker Johnson & Johnson expect to announce as early as Friday that contamination problems at a COVID-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.

Vaccine production at the plant run by contract manufacturer Emergent BioSolutions Inc. 

 was halted after unsanitary conditions led to contamination of J&J

vaccines. The facility made vaccine substance and finished vaccine doses for J&J and AstraZeneca 


Emergent chief executive Robert Kramer told a House committee last week that the company had produced enough of a key ingredient to yield more than 100 million doses of the J&J vaccine.

The company has been taking corrective measures and been in talks with FDA and J&J over the steps needed to reopen the facility.

An expanded version of this report appears on

Also popular on

Why a grand plan to vaccinate the world against COVID unraveled.

The Texas grid came close to an even bigger disaster during February freeze.

The Tell: Investors may be willing to sacrifice returns for ESG — but here’s where they haven’t had to, says Deutsche Bank

Previous article

MarketWatch First Take: The pandemic PC boom is still happening, but twin dangers loom

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *